Nurix Therapeutics Inc (NRIX)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$15.30

+0.46 (+3.10%)

Market Cap: $1.62B

Last updated: Nov 06, 2026 at 4:31 PM ET

Earnings

Performance (10Y)

Beat Rate

48%(12/25)

Avg Surprise

+33.04%

Streak

1 Q

Upcoming Estimates

Period ending Nov 30, 2026

EPS Consensus$-0.61

Range$-0.67 - $-0.53

3 analysts

Revenue Consensus

$9M

Range$-32261880 - $49M

4 analysts

Period ending Feb 28, 2027

EPS Consensus$-0.59

Range$-0.59 - $-0.59

1 analysts

EPS Revisions

30d

EPS Estimate DriftChange to current

90d ago$-0.57-3.1%

60d ago$-0.44-34.1%

30d ago$-0.44-34.1%

7d ago$-0.44-34.1%

Current$-0.59

Revenue Consensus

$15M

Range$15M - $15M

1 analysts

Last 12 of 27 reported quarters and 2 upcoming estimates

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Feb 28, 2027Feb 27EST	-	$-0.59	$-0.59 - $-0.59	-	-	1	4 0 30d	-
Nov 30, 2026Nov 26EST	-	$-0.61	$-0.67 - $-0.53	-	-	3	-	-
Aug 31, 2026Aug 26 Reported Oct 12, 2026Reported Oct 12	$4.73	$-0.56	$-1.38 - $0.07	+944.64%	Beat	3	2 0 30d	+559.2%
May 31, 2026May 26 Reported Jul 9, 2026Reported Jul 9	$-0.81	$-0.73	$-0.86 - $-0.50	-10.96%	Miss	14	1 1 30d	-55.8%
Feb 28, 2026Feb 26 Reported Apr 8, 2026Reported Apr 8	$-0.79	$-0.83	$-0.89 - $-0.65	+4.76%	Beat	12	5 1 30d	-17.9%
Nov 30, 2025Nov 25 Reported Jan 28, 2026Reported Jan 28	$-0.82	$-0.92	$-1.15 - $-0.72	+10.87%	Beat	12	No revisions (30d)	-9.3%
Aug 31, 2025Aug 25 Reported Oct 9, 2025Reported Oct 9	$-1.03	$-0.85	$-0.99 - $-0.68	-21.18%	Miss	15	5 10 30d	-53.7%
May 31, 2025May 25 Reported Jul 9, 2025Reported Jul 9	$-0.52	$-0.74	$-0.96 - $-0.60	+29.73%	Beat	15	1 0 30d	+26.8%
Feb 28, 2025Feb 25 Reported Apr 8, 2025Reported Apr 8	$-0.67	$-0.76	$-0.89 - $-0.58	+11.84%	Beat	13	0 6 30d	+11.8%
Nov 30, 2024Nov 24 Reported Jan 28, 2025Reported Jan 28	$-0.75	$-0.67	$-0.89 - $-0.54	-12.12%	Miss	13	7 2 30d	+2.6%
Aug 31, 2024Aug 24 Reported Oct 11, 2024Reported Oct 11	$-0.67	$-0.68	$-0.86 - $-0.60	+1.47%	Beat	12	No revisions (30d)	+1.5%
May 31, 2024May 24 Reported Jul 11, 2024Reported Jul 11	$-0.71	$-0.63	$-0.85 - $-0.40	-12.70%	Miss	12	3 0 30d	-57.8%
Feb 29, 2024Feb 24 Reported Apr 10, 2024Reported Apr 10	$-0.76	$-0.80	$-0.95 - $-0.64	+5.00%	Beat	10	No revisions (30d)	-1.3%
Nov 30, 2023Nov 23 Reported Feb 15, 2024Reported Feb 15	$-0.77	$-0.50	$-1.02 - $0.35	-54.00%	Miss	11	1 0 30d	+11.5%

Key Metrics

Valuation
P/E Ratio	6.62	EV/EBITDA	3.30x
Price/FCF	4.62x	FCF Yield	21.67%
Profitability
Profit Margin	42.00%	Operating Margin	83.10%
ROE	44.00%	ROIC	N/A
Financial Health
Debt/Equity	0.00x	Interest Coverage	N/A
Current Ratio	8.44x	Quick Ratio	8.44x
Trading Statistics
Beta	1.78	Avg Volume	3.86M
52-Week High	$28.23	52-Week Low	$12.01

Technical Indicators Dashboard

Moving Averages

SMA 10$23.10

SMA 20$23.81

SMA 50$24.26

SMA 200$20.19

EMA 10$21.15

EMA 20$22.80

EMA 50$23.72

EMA 200$20.87

MACD

Line: -1.50Signal: -0.25Hist: -1.25

ADX

ADX: 31.7+DI: 12.3-DI: 45.3

Aroon & PSAR

Aroon Up76.0

Aroon Down92.0

PSAR$26.86

Bollinger Bands

Upper Band$31.62

Lower Band$16.01

%B Position6554%(Upper)

Band Width-0.05

RSI (14-Day)

Oversold

22.3

Momentum Oscillators

Stoch %K4.4

Stoch %D22.0

Williams %R-96.1

ROC (10d)-39.6%

Momentum-10.04

CCI (20d)-201.6

MFI (14d)34.5

Volatility Measures

ATR (14d)$1.81(11.8%)

StdDev (20d)3.90

Hist Vol147.5%(High)

Volume Flow

VWAP$15.20

OBV26.3M

AD Line-38.4M

CMF (20d)-0.046

Volume Metrics

Avg Vol (20d)4.1M

Vol Ratio0.7x

VWMA (20d)$21.62

Pivot Points

R3$17.82

R2$17.21

R1$16.02

Pivot Point$15.41

S1$14.23

S2$13.62

S3$12.43

Advanced Oscillators

TSI-27.78

Ultimate Osc26.9

KST-23.36

Financial Data

Quarter	Aug 2026	May 2026	Feb 2026	Nov 2025	Aug 2025	May 2025	Feb 2025	Nov 2024	Aug 2024	May 2024	Feb 2024	Nov 2023
Total Revenue	$673.06M	$9.04M	$6.25M	$13.58M	$7.89M	$44.06M	$18.45M	$13.28M	$12.59M	$12.09M	$16.59M	$15.16M
Cost of Revenue	$0	$0	$0	$4.63M	$0	$0	$0	$67.22M	$0	$0	$0	$49.71M
Gross Profit	$673.06M	$9.04M	$6.25M	$13.58M	$7.89M	$44.06M	$18.45M	$13.28M	$12.59M	$12.09M	$16.59M	$15.16M

Operating Expenses	$113.61M	$103.25M	$98.75M	$96.67M	$99.28M	$92.38M	$81.32M	$77.94M	$67.20M	$60.63M	$61.80M	$60.49M
R&D	$79.26M	$87.65M	$84.14M	$83.02M	$86.12M	$78.10M	$69.66M	$67.22M	$55.48M	$48.92M	$50.01M	$49.71M
SG&A	$34.35M	$15.59M	$14.61M	$13.65M	$13.16M	$14.28M	$11.65M	$10.72M	$11.72M	$11.71M	$11.80M	$10.78M
Operating Income	$559.45M	$-94,204,000	$-92,495,000	$-83,095,000	$-91,385,000	$-48,322,000	$-62,864,000	$-64,657,000	$-54,611,000	$-48,540,000	$-45,219,000	$-45,334,000

Interest Income	$3.96M	$4.40M	$5.32M	$4.87M	$4.96M	$5.62M	$6.51M	$6.12M	$5.74M	$4.08M	$3.79M	$3.38M
Interest Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Income Before Tax	$563.41M	$-89,806,000	$-87,174,000	$-78,221,000	$-86,421,000	$-42,704,000	$-56,351,000	$-58,541,000	$-48,874,000	$-44,456,000	$-41,428,000	$-41,956,000
Income Tax Expense	$13.61M	$-271,000	$0	$0	$0	$760,000	$0	$8,000	$82,000	$90,000	$90,000	$0

Net Income	$549.81M	$-89,535,000	$-87,174,000	$-78,221,000	$-86,421,000	$-43,464,000	$-56,351,000	$-58,549,000	$-48,956,000	$-44,546,000	$-41,518,000	$-41,956,000

EBITDA	$562.13M	$-91,911,000	$-90,697,000	$-80,331,000	$-88,582,000	$-45,926,000	$-62,293,000	$-63,847,000	$-54,171,000	$-46,608,000	$-43,261,000	$-43,545,000
EBIT	$559.45M	$-94,204,000	$-92,495,000	$-83,095,000	$-91,385,000	$-48,322,000	$-62,864,000	$-64,657,000	$-54,611,000	$-48,540,000	$-45,219,000	$-45,334,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about NRIX

News

Nurix Therapeutics, Inc. $NRIX Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. reduced its stake in Nurix Therapeutics (NASDAQ:NRIX) by 12.2% in the third quarter, selling 120,385 shares...

MarketBeat•Nov 6, 2026 5:58 AM ET11/6/26•Neutral

An experimental blood cancer drug showed high response rates in previously treated patients.

Nurix Therapeutics will present updated data for its investigational drug, bexobrutideg (NX-5948), at the 68th ASH Annual Meeting in December 2026. The Phase 1a/1b trial showed high response rates...

Stock Titan•Nov 5, 2026 6:40 AM ET11/5/26•Neutral

Form 4 Nurix Therapeutics Inc: Hans van Houte (CFO) For: 4 November By Investing.com

This article reports a Form 4 filing for Nurix Therapeutics Inc., indicating an insider transaction by Chief Financial Officer Hans van Houte on November 4th. The filing is provided by Investing.com...

Investing.com India•Nov 4, 2026 5:41 PM ET11/4/26•Neutral

Sanofi Decides to Stop Studies of Nurix-Partnered Experimental Drug

Sanofi has decided to halt studies on an experimental inflammatory disease therapy developed in partnership with Nurix Therapeutics. This news led to an extended decline in Nurix Therapeutics' shares...

www.tokenpost.com•Nov 4, 2026 5:40 PM ET11/4/26•Bearish

A 4,769-share sale is proposed by Nurix Therapeutics (NRIX) officer Johannes van Houte.

Nurix Therapeutics (NRIX) officer Johannes van Houte has proposed selling 4,769 common shares, valued at approximately $123,135.58, with an approximate sale date of November 4...

Stock Titan•Nov 4, 2026 4:41 PM ET11/4/26•Neutral

NRIX Valuation and Fair Value

P/E: 6.6x
EV/EBITDA: 3.3x
P/FCF: 4.6x
P/B: 1.8x

See GNG's fair value

NRIX Profitability: Margins, ROIC and FCF

Gross margin: 100.0%
Operating margin: 83.1%
Net margin: 42.0%
ROE: 44.0%
FCF yield: 21.7%

NRIX Competitors

Company	Ticker
Butterfly Network Inc	BFLY
Novavax Inc	NVAX
Forte Biosciences Inc	FBRX
Sellas Life Sciences Group Inc	SLS
Personalis Inc	PSNL
Ultragenyx	RARE
Zenas BioPharma, Inc. Common Stock	ZBIO
Alignment Healthcare LLC	ALHC

Sector: Healthcare

NRIX Analyst Ratings

Consensus: Buy
Analysts: 14
Strong Buy: 5
Buy: 8
Hold: 1
Sell: 0
Strong Sell: 0

NRIX Bull Case vs Bear Case

Bull case

NRIX has a 42.0% net profit margin.
NRIX grew quarterly revenue 8426.0% year over year.
92.9% of NRIX's analyst ratings are Buy or Strong Buy.

NRIX Earnings: Beat Rate and Next Report

Beat rate: 5 of 8 quarters (62.5%)
Average surprise: 119.7%
EPS estimate (fiscal period ending Nov 30, 2026): $-0.61

NRIX Earnings Date

NRIX reports Jan 26, 2027, after the close. The date is estimated.

NRIX ETF Holders

GNG tracks 14 ETFs that hold NRIX. The largest weights:

ARK Genomic Revolution ETF (ARKG), 2.69% of the fund
State Street SPDR S&P Biotech ETF (XBI), 0.58% of the fund
First Trust Small Cap Growth AlphaDEX Fund (FYC), 0.41% of the fund
iShares Biotechnology ETF (IBB), 0.18% of the fund
Fidelity Enhanced Small Cap Core ETF (FESM), 0.09% of the fund

Open the ETF Stock Exposure tool for NRIX

See insider activity

Frequently Asked Questions About NRIX

When does NRIX report earnings?

Nurix Therapeutics Inc (NRIX) is expected to report earnings on Jan 26, 2027.

Does NRIX pay dividends?

Nurix Therapeutics Inc (NRIX) does not currently pay a regular dividend.

What is NRIX's P/E ratio?

Nurix Therapeutics Inc has a price-to-earnings (P/E) ratio of 6.62.

What is NRIX's market cap?

Nurix Therapeutics Inc (NRIX) has a market capitalization of $1.62B with a current stock price of $15.30.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In